- Home
- GORV vs RNAZ Comparison
GORV vs RNAZ Comparison
Compare GORV & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- RNAZ
- Stock Information
- Founded
- GORV 1976
- RNAZ 2016
- Country
- GORV United States
- RNAZ United States
- Employees
- GORV N/A
- RNAZ N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- RNAZ Health Care
- Exchange
- GORV Nasdaq
- RNAZ Nasdaq
- Market Cap
- GORV 10.6M
- RNAZ 8.7M
- IPO Year
- GORV 2015
- RNAZ 2021
- Fundamental
- Price
- GORV $2.52
- RNAZ $12.22
- Analyst Decision
- GORV
- RNAZ Strong Buy
- Analyst Count
- GORV 0
- RNAZ 1
- Target Price
- GORV N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- GORV 1.7M
- RNAZ 13.8K
- Earning Date
- GORV 11-17-2025
- RNAZ 11-13-2025
- Dividend Yield
- GORV N/A
- RNAZ N/A
- EPS Growth
- GORV N/A
- RNAZ N/A
- EPS
- GORV N/A
- RNAZ N/A
- Revenue
- GORV $662,952,000.00
- RNAZ N/A
- Revenue This Year
- GORV $15.65
- RNAZ N/A
- Revenue Next Year
- GORV $20.54
- RNAZ N/A
- P/E Ratio
- GORV N/A
- RNAZ N/A
- Revenue Growth
- GORV N/A
- RNAZ N/A
- 52 Week Low
- GORV $2.04
- RNAZ $6.15
- 52 Week High
- GORV $58.80
- RNAZ $739.20
- Technical
- Relative Strength Index (RSI)
- GORV 46.29
- RNAZ 63.85
- Support Level
- GORV $2.04
- RNAZ $10.32
- Resistance Level
- GORV $3.10
- RNAZ $12.28
- Average True Range (ATR)
- GORV 0.27
- RNAZ 0.72
- MACD
- GORV 0.10
- RNAZ 0.12
- Stochastic Oscillator
- GORV 47.17
- RNAZ 97.52
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.